Biomissile, a clinical stage biotech company focusing on developing fully human domain antibody (UDAB^TM) and multi-specific antibody (UDAB-M^TM) recently announced the first subject was successfully dosed on June 14, 2023 for BM012 in a Phase I trial. BM012 (HT-102) is jointly developed by Biomissile and Suzhou Hepa Thera Biotech for the functional cure of HBV.

Preclinical studies have shown that BM012 (HT-102) could rapidly clear HBsAg and HBV DNA from systemic circulation. BM012 combined with another new hepatitis B drug HT-101 siRNA injection can effectively reduce S antigen and show more durable antiviral activity, which has significant synergistic effect. The two drug candidates will be used jointly in the future clinical research, providing new hopes for the functional cure of hepatitis B.

About BM012 
https://mp.weixin.qq.com/s/BGrbGNW2QnHzgI56OkNqyg
https://mp.weixin.qq.com/s/pnLg7-JYrtWvGiGLIumRcA

About Biomissile

Biomissile Pharmaceuticals Co., Ltd. is a clinical stage biotech company focusing on developing fully human domain antibody (UDAB^TM) and multi-specific antibody (UDAB-M^TM) to fight a range of diseases with global unmet medical needs. We aim to become a premium innovative biopharmaceutical company based on our unique platform technologies, strong pipeline, and outstanding team. We have established five proprietary platforms for rapid antibody discovery and optimization, including the leading platforms for fully human domain antibody (UDAB^TM) and multi-specific antibody (UDAB-M^TM), as well as the largest libraries of phage, yeast and mammalian cell display platforms. Relying on the strong platform technologies, the company has more than 10 innovative candidates under development in a short period of time, including several First-in-Class domain antibodies (VH) and multi-specific UDAB-M molecules to specifically activate immune cells in the tumor microenvironment (TME). 

Biomissile has successfully assembled a seasoned leadership team in antibody discovery, manufacturing, clinical, registration and business development. The core team members are composed of experts with an average of more than 20 years’ experience in biological R&D and commercialization. The company has a state-of-the-art R&D lab in Zhangjiang, Shanghai, a GMP facility in Wuzhong, Suzhou under construction, and a global regulatory and BD team in Boston, USA.

Link to the news in Chinese:
https://mp.weixin.qq.com/s/JcqQam3XEy-cIA2ksJY_4g